Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
8
×
life sciences
national blog main
biotech
boston
boston top stories
clinical trials
national top stories
san francisco blog main
fda
new york blog main
startups
deals
atlas venture
cancer
decibel therapeutics
dyne therapeutics
gene therapy
hearing loss
investing
kaleido biosciences
myotonic dystrophy type 1
new york top stories
rare disease drugs
regenerative medicine
san diego blog main
sanofi
vc
adeno-associated virus
akili interactive labs
akouos
allosteric
astellas pharma
astellas pharmaceuticals
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
azacitidine
beta-thalassemia
What
medicines
8
×
therapeutics
8
×
drug
ipo
ago
developing
new
biotech
clinic
drugs
dyne
field
genetic
hearing
loss
muscle
rare
regenerative
research
targets
years
adding
address
adds
affects
aiming
aims
allosteric
americans
announced
approach
approved
backs
balance
based
bets
biotechs
black
brings
build
Language
unset
Current search:
medicines
×
therapeutics
×
" boston blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum